| Note: This medical device record is a PMA supplement. A supplement may have changed the device description/function or indication from that approved in the original PMA. Be sure to look at the original PMA record for more information. |
| |
| Device | PD-L1 IHC 22C3 pharmDx |
| Generic Name | Immunohistochemistry assay, antibody, programmed death-ligand 1 |
| Applicant | Agilent Technologies, Inc. 5301 Stevens Creek Blvd. Santa Clara, CA 95051 |
| PMA Number | P150013 |
| Supplement Number | S022 |
| Date Received | 11/16/2020 |
| Decision Date | 01/31/2022 |
| Product Code |
PLS |
| Advisory Committee |
Pathology |
| Supplement Type | Normal 180 Day Track No User Fee |
| Supplement Reason | Labeling Change - PAS |
| Expedited Review Granted? | No |
| Combination Product | No |
| Predetermined Change Control Plan Authorized | No |
Approval Order Statement Approval of the final report for the External Reproducibility Study (Part B – Inter-Observer) using the PD-L1 IHC 22C3 pharmDx in esophogeal squamous cell carcinoma specimens and the proposed changes to the labeling to include the results of this study. |
|
|